current
standard
care
therapi
hepat
c
viru
hcv
infect
consist
two
regim
name
interferonbas
interferonfre
treatment
treatment
combin
ribavirin
pegyl
interferon
expens
mildli
effect
associ
sever
side
effect
two
directact
antivir
daa
drug
boceprevir
telaprevir
licens
shown
enhanc
sustain
virolog
respons
svr
phase
iii
clinic
trial
howev
interferonfre
treatment
sensit
hcv
genotyp
infect
variabl
natur
hcv
limit
number
inhibitor
develop
thu
aim
expand
repertoir
avail
drug
target
result
target
viru
assembl
therapeut
hcv
genotyp
furthermor
conduct
quantit
structureact
relationship
dock
interact
studi
drug
nbdnj
form
highest
number
hydrogen
bond
interact
model
protein
high
interact
energi
follow
flavonoid
screen
demonstr
epigallocatechin
gallat
egcg
nobiletin
quercetin
bind
mode
thu
predict
protein
molecul
hcv
provid
gener
avenu
target
structurebas
antivir
compound
hypothes
inhibitor
viral
identifi
screen
may
new
class
potent
agent
confirm
vitro
vivo
essenti
structureguid
drug
design
lead
identif
druglik
natur
compound
confirm
new
target
rapidli
increas
era
hcv
comput
dock
studi
ion
channel
genotyp
plo
one
conduct
studi
predict
structur
protein
hcv
genotyp
approxim
amino
acid
residu
encod
hcv
render
channel
sensit
inhibitor
make
promis
target
novel
therapi
hcv
protein
form
small
membran
known
viroporin
essenti
effect
selfassembl
larg
channel
conduct
cation
assembl
discharg
infecti
virion
particl
studi
screen
drug
flavonoid
known
disrupt
translat
product
hcv
protein
target
activ
site
residu
hcv
genotyp
hepat
c
viru
hcv
chronic
affect
approxim
million
peopl
worldwid
hcv
infect
individu
risk
liver
cirrhosi
well
hepatocellular
carcinoma
envelop
hcv
belong
famili
flavivirida
seven
main
genotyp
roughli
subtyp
accord
wide
geograph
distribut
hcv
hcv
genotyp
gt
distribut
worldwid
common
subtyp
account
global
hcv
infect
hcv
subtyp
prevail
eastern
europ
japan
north
america
remain
less
frequent
report
endem
southeast
asia
unevenli
distribut
variou
countri
around
world
larg
found
middl
east
central
africa
egypt
almost
exclus
found
south
africa
gt
scatter
across
asia
current
treatment
rout
limit
interferonbas
interferonfre
regimen
ribavirin
combin
therapi
limit
variabl
effect
depend
hcv
genotyp
host
immun
respons
usa
simeprevir
fda
approv
proteas
inhibitor
also
dose
along
pegifn
ribavirin
tripl
therapi
recent
food
drug
administr
fda
european
medicin
agenc
emea
approv
two
directact
antivir
daa
name
boceprevir
telaprevir
proteas
inhibitor
shown
promis
sustain
virolog
respons
svr
phase
iii
clinic
trial
howev
genotyp
specif
combin
therapi
oral
drug
also
licens
fda
includ
sofosbuvir
nucleotid
analog
inhibit
rna
polymeras
combin
ribavirin
oral
dual
therapi
hcv
well
sofosbuvir
combin
viral
inhibitor
ledipasvir
treatment
infect
respect
least
addit
daa
variou
stage
clinic
develop
hcv
genom
express
larg
polyprotein
cleav
proteas
array
protein
singlestrand
rna
genom
encod
structur
protein
includ
core
glycoprotein
along
nonstructur
protein
ion
channel
posit
middl
structur
protein
nonstructur
protein
hcv
viral
channelform
protein
compris
two
elong
hydrophob
transmembran
tm
domain
link
cytosol
loop
howev
structur
inform
ion
channel
known
includ
protein
oligomer
well
fold
helic
hexamer
bundl
structur
report
first
time
nuclear
magnet
reson
nmr
spectroscop
studi
threedimension
structur
hexam
gener
use
comput
method
recent
advanc
comput
techniqu
enabl
us
build
small
protein
molecul
portion
larger
protein
molecul
reason
good
resolut
variou
approach
develop
adopt
includ
combin
model
molecular
dock
molecular
dynam
simul
computermodel
protein
guid
knowledg
membran
protein
fold
insert
lipid
membran
membran
protein
translat
aid
translocon
translocon
membranespan
protein
enabl
primari
sequenc
membran
protein
form
secondari
structur
within
hydrophob
region
lipid
membran
final
topolog
membran
protein
dictat
prime
amino
acid
sequenc
protein
protein
final
releas
lipid
bilay
thu
secondari
structur
form
protein
retain
fold
structur
viral
channelform
protein
also
built
alon
use
comput
techniqu
apart
form
selfassembl
sophist
funnellik
architectur
select
conduct
cation
protein
also
play
crucial
role
viral
assembl
envelop
process
coordin
protein
steinmann
cowork
shown
product
viral
particl
genotypespecif
due
interact
viral
factor
howev
interact
pattern
protein
viral
host
factor
well
exact
contribut
viral
product
remain
uncertain
recent
coimmunoprecipit
studi
use
replicationcompet
viru
contain
doubl
hatag
perform
vieyr
cowork
endors
format
specif
interact
highlight
import
viru
product
cell
cultur
although
basic
fundament
structur
becom
gradual
understood
condit
lead
disrupt
assembl
function
channel
well
mechan
druginteract
unknown
furthermor
absenc
clinic
effici
current
inhibitor
cast
doubt
precis
antivir
effect
adamantin
rimantadin
alkyl
imino
sugar
known
identifi
particular
resist
mutat
ascrib
method
inhibit
sensit
ion
channel
activ
inhibit
report
vitro
hexamethylen
chlorid
adamantin
well
long
chain
imino
sugar
inhibitor
activ
certain
hcv
genotyp
variou
group
report
differ
sensit
present
interferonbas
therapi
hcv
infect
patient
insuffici
stimul
rout
combin
directact
antivir
daa
sever
compound
target
three
nonstructur
viral
protein
proteas
polymeras
still
must
assess
oligomer
phospholipid
membran
form
cationselect
ion
channel
known
drug
target
region
molecular
activ
protein
far
character
also
group
famili
viroporin
vpu
influenza
protein
viroporin
inhibitor
rimantidin
amantadin
first
approv
year
ago
antiinfluenza
drug
prove
effect
pharmacolog
expans
class
antivir
complex
rimantidin
amantadin
hinder
influenza
obstruct
h
conduct
via
ion
channel
therebi
disturb
conform
chang
viral
protein
requir
viral
replic
recent
shown
mediat
cation
conduct
inhibit
adamantin
long
alkyl
chain
imino
sugar
amilorid
vitro
vari
report
efficaci
addit
known
precis
interact
nonstructur
protein
indic
channel
activ
regul
silico
approach
combin
global
search
engin
macromoleculeligand
comput
dock
appli
creat
best
possibl
model
assembl
compar
inhibitori
efficaci
three
report
inhibitor
studi
present
model
monomer
structur
asia
middl
east
develop
structur
evalu
protein
simul
procheck
addit
dock
select
ligand
activ
site
region
model
structur
genotyp
focus
construct
evalu
structur
repres
type
interact
made
residu
model
result
reveal
possibl
role
residu
interact
ion
channel
like
futur
inhibitor
natur
compound
test
multipl
genotyp
determin
potenti
clinic
efficaci
sequenc
ion
channel
consist
amino
acid
retriev
uniprotkb
ensur
select
viral
strain
use
homo
sapien
host
tabl
uniprotkb
entri
strain
hcv
hcv
strain
hcv
strain
strain
strain
hcv
strain
multipl
sequenc
align
done
fasta
format
ion
channel
genotyp
use
ibivu
server
pralin
multipl
sequenc
align
use
weight
matrix
algorithm
gap
penalti
extens
valu
respect
psiblast
preprofil
process
homologyextend
align
use
progress
align
strategi
align
also
base
structur
featur
use
dsspdefin
secondari
structur
use
psipr
method
phylogenyfr
platform
use
gener
phylogenet
tree
hcv
genotyp
order
find
evolutionari
relationship
among
process
step
multipl
align
refin
done
use
program
call
muscl
gblock
respect
paramet
valu
use
minimum
number
sequenc
conserv
posit
minimum
number
sequenc
flank
posit
maximum
number
contigu
non
conserv
posit
respect
phylogenet
tree
construct
visual
phyml
treedyn
program
respect
branch
support
display
color
red
estim
approxim
likelihood
ratio
test
alrt
method
implement
phyml
protein
sequenc
hcv
ion
channel
retriev
swiss
prot
databas
contain
amino
acid
residu
clustalw
use
multipl
sequenc
align
protein
fasta
sequenc
preval
hcv
hcv
asia
middl
east
multipl
align
paramet
includ
weight
matrix
use
blosum
gap
open
penalti
gap
extens
penalti
valu
respect
asia
middl
east
multipl
align
paramet
includ
weight
matrix
use
blosum
gap
open
penalti
gap
extens
penalti
valu
respect
crystal
structur
hepat
c
viru
pdb
entri
identifi
homolog
protein
domain
respect
use
blast
pdb
databas
crystal
structur
use
templat
model
ion
channel
hcv
energi
minim
model
protein
done
use
modrefin
follow
twostep
procedur
construct
fullatom
model
first
step
build
backbon
avail
calpha
perform
energi
minim
improv
qualiti
follow
second
step
add
side
chain
atom
rotam
librari
conduct
energi
minim
side
chain
backbon
conform
final
refin
model
hcv
valid
use
procheck
structur
analysi
verif
server
calcul
ramachandran
plot
superpos
version
use
analyz
energi
criteria
model
protein
genotyp
templat
structur
calcul
root
mean
squar
deviat
rmsd
valu
templat
structur
four
avail
drug
molecul
longalkylchain
iminosugar
deriv
nbutyldeoxynojirimycin
nbdnj
hexamethylen
amilorid
amantadin
obtain
pubchem
similarli
chemic
structur
natur
molecul
antivir
properti
also
drawn
use
acd
chemsketch
charmm
forc
field
appli
energi
minim
obtain
converg
gradient
use
charmm
boundari
potenti
builder
repres
tabl
virtual
model
properti
evalu
chemic
within
global
architecturequantit
structureact
relationship
vegaqsar
program
use
analyz
select
ligand
determin
relationship
physiochem
properti
biolog
activ
descriptor
molecul
variou
classifi
qsar
model
qsar
model
initi
summar
theoret
relationship
chemic
structur
biolog
activ
dataset
chemic
secondli
qsar
model
determin
activ
new
chemic
compound
toxic
ecotox
predict
physiochem
properti
ligand
logp
caesarvers
compar
molecular
dock
studi
hcv
select
molecul
perform
use
clc
drug
discoveri
workbench
follow
templat
dock
algorithm
use
moldock
score
function
bind
energi
calcul
molecul
project
system
initi
use
upload
pdb
file
model
structur
contain
bind
site
setup
input
small
molecul
molecul
tabl
dock
simul
search
optim
bind
mode
bind
site
maximum
bind
mode
ligand
protein
gener
use
default
paramet
clc
drug
discoveri
dock
score
use
drug
discoveri
workbench
plant
plp
score
score
good
balanc
accuraci
evalu
time
score
mimic
potenti
energi
chang
protein
ligand
come
togeth
mean
neg
score
correspond
strong
bind
less
neg
even
posit
score
correspond
weak
nonexist
bind
base
number
hbond
interact
dock
score
bestrank
compound
select
detail
bind
interact
studi
ligandprotein
complex
visual
clc
drug
discoveri
visual
tool
amino
acid
sequenc
ion
channel
complet
hcv
genotyp
align
gener
maximum
likelihood
tree
phyml
diverg
outgroup
subtyp
result
phylogenet
analys
summar
fig
ion
channel
show
closer
similar
within
differ
strain
subtyp
b
strain
subtyp
similar
subtyp
subtyp
predict
maximum
like
strain
subtyp
form
cluster
indic
low
sequenc
variat
compar
subtyp
show
maximum
similar
slightli
distribut
branch
lead
long
potenti
time
evolv
root
clade
less
diverg
among
subtyp
compar
vast
diverg
base
tree
hcv
subtyp
cluster
divers
global
subtyp
wherea
subtyp
cluster
togeth
respect
clade
among
phylogeni
subtyp
form
cluster
divers
subtyp
within
core
phylogeni
strain
present
separ
cluster
possibl
due
less
bootstrap
support
aris
inadequ
phylogenet
detail
similarli
strain
cluster
outsid
compar
subtyp
subtyp
genet
divers
distribut
throughout
tree
tend
found
base
hcv
branch
amino
acid
substitutionmut
rate
per
site
protein
among
genotyp
hcv
found
mean
viru
accumul
signific
number
substitut
therebi
phylogenet
analysi
hcv
genotyp
isol
differ
strain
refer
strain
variou
part
world
divulg
great
genom
divers
less
divers
moder
divers
multipl
sequenc
align
consensu
sequenc
isol
studi
shown
fig
exact
hcv
subtyp
repres
subtyp
strain
asia
ident
new
zealand
strain
percent
sequenc
ident
among
differ
subtyp
vari
similarli
consensu
sequenc
align
hcv
subtyp
also
perform
show
maximum
ident
wherea
percent
sequenc
ident
among
differ
subtyp
vari
observ
less
variat
residu
ctermin
region
compar
loop
region
ntermin
region
sequenc
subtyp
consist
mutat
posit
could
consid
novel
amino
acid
residu
vari
particular
posit
sequenc
compar
sequenc
align
also
perform
separ
subtyp
well
subtyp
identifi
sequenc
maximum
conserv
residu
target
region
interact
protein
residu
ligand
molecul
defin
therefor
subtyp
subtyp
taken
homolog
model
show
maximum
similar
respect
genotyp
compar
subtyp
multipl
sequenc
align
protein
fasta
sequenc
complet
set
sequenc
genotyp
also
analyz
highlight
conserv
mutat
region
present
dataset
queri
refer
sequenc
hcv
hcv
target
sequenc
use
blastp
protein
basic
local
align
search
tool
search
blastp
search
reveal
sever
sequenc
homolog
ion
channel
measl
viru
phosphoprotein
pdb
code
chosen
best
templat
model
model
chain
maximum
ident
select
genotyp
chosen
templat
sequenc
atom
structur
stabl
domain
measl
viru
phosphoprotein
tight
fourstrand
coil
coil
consist
chain
b
c
e
f
g
h
crystal
structur
determin
use
xray
diffract
resolut
observ
one
probabl
quaternari
state
obtain
tetramer
domain
measl
viru
phosphoprotein
ident
target
queri
coverag
accordingli
gener
macromolecul
amino
acid
residu
target
base
align
model
amino
acid
sequenc
chain
measl
viru
phosphoprotein
homolog
model
procedur
model
ion
channel
evalu
use
procheck
tool
stereochem
qualiti
use
ramachandran
plot
determin
model
approxim
aa
favor
region
less
residu
allow
region
residu
disallow
region
tabl
indic
predict
model
highli
reliabl
comput
studi
fig
model
sequenc
align
within
denot
fig
multipl
sequenc
align
hcv
sequenc
align
hcv
subtyp
use
clustalw
program
conserv
residu
sequenc
highlight
black
color
denot
residu
share
similar
less
similar
properti
posit
respect
highlight
denot
common
residu
posit
sequenc
show
maximum
similar
compar
strain
isolatetrkj
sequenc
align
also
perform
within
subtyp
use
clustalw
tool
conserv
region
share
similar
sequenc
highlight
black
subtyp
show
much
variat
ntermin
region
follow
loop
region
compar
ctermin
region
comput
dock
studi
ion
channel
genotyp
denot
threedimension
structur
type
protein
model
rmsd
valu
calcul
mainchain
atom
model
templat
indic
close
homolog
ensur
reliabl
model
vegaqsar
analysi
carri
predict
differ
biochem
properti
potenti
ligand
result
attain
qsar
model
could
effect
evalu
chemic
properti
chosen
compound
decreas
necess
anim
test
differ
model
test
antivir
compound
tabl
select
compound
posit
neg
predict
includ
mutagen
carcinogen
fathead
minnow
predict
less
log
moll
select
compound
comput
dock
studi
ion
channel
genotyp
except
egcg
honokiol
log
moll
log
mol
l
respect
compound
sensit
skin
except
egcg
nbdnj
known
nontox
compar
select
ligand
apigenin
luteolin
biodegrad
select
compound
noncarcinogen
except
naringenin
silymarin
quercetin
qsar
model
predict
hexamethylen
chlorid
nbdnj
mutagen
log
p
valu
valuabl
paramet
understand
behavior
drug
molecul
log
p
valu
higher
honokiol
log
unit
nobiletin
log
unit
apigenin
nbdnj
log
p
valu
less
log
unit
dock
select
drug
clc
molecul
project
entri
dock
result
display
togeth
protein
molecul
project
visual
bind
mode
ligand
bind
site
creat
interact
atom
group
option
use
gener
custom
atom
group
consist
protein
residu
molecul
least
one
heavi
atom
within
ligand
heavi
atom
hcv
distinguish
three
region
loop
region
includ
residu
termin
region
includ
residu
respect
nand
ctermin
site
bind
affin
along
rerank
score
calcul
best
complex
nbdnj
form
maximum
hbond
exhibit
highest
bind
affin
kcalmol
kcalmol
respect
nbdnj
ligand
select
drug
exhibit
larger
number
interact
residu
nbdnj
capabl
form
hydrogen
bond
larg
aliphat
chain
therebi
largest
number
rotat
bond
protein
residu
form
one
hbond
residu
carbon
atom
amantadin
hexamethylen
chlorid
interact
chain
best
interact
observ
dock
studi
nbdnj
residu
compar
genotyp
model
amantadin
extend
one
hbond
interact
ion
channel
fig
dock
result
indic
ctermin
ntermin
side
region
contain
potenti
drug
interact
site
tabl
known
antivir
drug
amantadin
may
less
bind
affin
compar
nbdnj
howev
differ
signific
hcv
leon
et
al
also
report
amantadin
exhibit
weaker
bind
energi
due
interact
loop
region
protein
hcv
base
interact
energi
residu
form
hbond
compound
rank
follow
descend
order
respect
predict
effect
bind
nbdnj
amantadin
hexamethylen
chlorid
dock
experi
conduct
silico
method
shown
video
file
possibl
bind
site
flavonoid
compound
use
ion
channel
model
show
interact
flavonoid
phenol
involv
inhibit
two
main
factor
critic
success
ligandprotein
dock
studi
first
energi
function
bind
protein
second
number
hydrogen
bond
form
bind
mode
model
egcg
lowest
bind
energi
due
bind
interact
form
mani
hbond
howev
worth
mention
egcg
effect
hcv
rna
replic
assembl
releas
progeni
virion
therefor
strong
bind
egcg
may
assum
inhibit
cell
cell
spread
viru
block
ion
channel
process
protein
therebi
disrupt
initi
step
hcv
cell
entri
quercetin
form
hbond
tabl
luteolin
silymarin
form
four
hbond
apigenin
luteolin
interact
residu
ntermin
site
comput
dock
studi
ion
channel
genotyp
form
hbond
protein
residu
ladanein
naringenin
exhibit
high
bind
energi
valu
interact
model
hcv
protein
analyz
energi
valu
hcv
model
bind
conform
score
much
higher
compar
hcv
model
howev
number
interact
form
natur
molecul
hcv
model
significantli
higher
bind
mode
drug
interact
hcv
fig
interact
form
natur
molecul
target
bind
loop
region
essenti
mechan
function
hcv
possibl
bind
site
phenol
compound
analyz
reliabl
interact
mode
look
energi
function
score
phenol
compound
within
hcv
dock
score
lower
honokiol
form
hbond
shown
tabl
wherea
nobiletin
form
higher
dock
score
kcalmol
form
interact
interact
observ
nand
ctermin
region
model
case
phenol
compound
notabl
hcv
decreas
bind
energi
valu
hbond
interact
observ
fig
current
antivir
strategi
play
vital
role
viral
assembl
discharg
matur
viral
particl
thu
highli
conserv
across
hcv
genotyp
make
excel
potenti
latent
antivir
drug
target
comput
dock
studi
ion
channel
genotyp
amantadin
long
alkyl
chain
immunosugar
deriv
hexamethylen
amilorid
establish
channelblock
compound
shown
protein
interact
nonstructur
protein
hcv
present
endoplasm
reticulum
interfac
crucial
infect
viru
inhibitor
exhibit
antivir
activ
cell
cultur
report
larg
variou
experi
studi
viroporin
variou
virus
inhibitor
includ
amantadin
known
inhibit
influenza
viru
channel
hexamethylen
amilorid
known
inhibit
vpu
ion
channel
longalkylchain
iminosugar
deriv
amantadin
amantadin
chemic
known
hydrochlorid
dual
pharmacolog
action
treat
viral
parkinson
diseas
mechan
action
mainli
inhibit
releas
viral
dna
host
cell
interact
function
transmembran
domain
protein
respect
high
preval
rate
drugresist
viru
consumpt
amantadin
deriv
like
rimantidin
treat
prophylaxi
propos
countri
like
usa
smith
cowork
studi
effect
treatment
use
amantadin
patient
affect
hcv
earlier
known
fail
respond
interferon
therapi
howev
studi
fail
approv
posit
effect
interferon
therapi
well
still
hope
amantadin
observ
inhibit
function
artifici
membran
well
cellbas
assay
turn
inhibit
activ
viral
hepat
griffin
et
al
valid
variou
inhibitor
molecul
hcv
cell
line
vitro
assay
parallel
approach
identifi
inhibit
viral
entri
compound
denot
antivir
activ
specif
block
function
ion
channel
amilorid
amilorid
categor
guanidium
group
compound
contain
pyrazin
deriv
function
block
sodium
channel
present
epitheli
tissu
therebi
render
sodium
reabsorpt
kidney
result
deplet
sodium
bodi
without
lose
potassium
vpuprotein
similar
form
cation
channel
vitro
improv
bud
therebi
releas
viru
infecti
particl
ewart
et
al
team
discuss
vpuprotein
similar
properti
releas
viral
particl
bud
studi
valid
deriv
amilorid
retard
activ
ion
channel
result
bud
trigger
vpu
recent
hexamethylen
amilorid
deriv
amilorid
known
inhibit
activ
ion
channel
studi
cell
toxic
vari
drug
concentr
requir
cell
cultur
attain
inhibit
preclud
strong
decis
regard
inhibitori
influenc
amilorid
infecti
viru
particl
synthes
tissu
cultur
system
iminosugar
deriv
iminosugar
deoxynojirimycin
dnj
monosaccharid
sugar
molecul
oxygen
ring
substitut
nitrogen
atom
glucosederiv
dnj
nnonyldnj
nbutyldnj
effect
inhibitor
er
ii
experi
hcv
surrog
model
wellknown
elimin
glucos
molecul
nlink
glycan
present
high
manos
bond
henc
process
step
vital
interact
er
chaperon
glycoprotein
thu
compound
compris
dnj
header
group
along
long
alkyl
side
chain
known
dual
role
inhibit
activ
er
becom
barrier
channel
function
due
nonrespond
therapi
new
deriv
compound
call
nndnj
enter
clinic
phase
ii
studi
antivir
efficaci
yet
confirm
latest
experiment
drug
develop
biotron
limit
treat
hcv
hiv
infect
moreov
capabl
block
vpu
ion
channel
function
disrupt
hiv
assembl
host
white
blood
cell
also
express
antivir
synergi
polymeras
inhibitor
ribavirin
drug
credit
target
ion
channel
activ
effici
accomplish
phase
ia
healthi
volunt
singl
dose
trial
phase
ib
assess
pharmacokinet
frequent
medic
certain
dose
hcv
affect
patient
studi
three
dimension
structur
ion
channel
model
use
precis
comput
tool
ion
channel
protein
hcv
model
absenc
complet
structur
henc
highresolut
templat
structur
use
studi
report
regard
variou
drug
bind
site
stabil
close
channel
alloster
mechan
propos
controversi
studi
iav
still
assum
fold
character
hairpin
still
remain
indistinct
regard
rearrang
protein
structur
monom
hexam
form
fascinatingli
amiloridebas
inhibitor
present
clinic
trial
combin
ribavirin
interferon
conclud
depth
number
residu
bind
mode
nativ
bind
energi
obscur
chang
protein
structur
two
genotyp
work
molecular
dock
perform
natur
occur
plant
extract
four
known
drug
inhibit
activ
loop
region
found
harbor
residu
necessari
mechan
function
also
hypothes
bind
ligand
molecul
loop
region
inactiv
essenti
dynam
requir
protein
drug
variabl
level
interact
gt
gt
antivir
drug
whose
effect
limit
may
effect
current
onesizefitsal
treatment
avail
sequenc
variat
genotyp
valid
determin
specif
gt
gt
well
sequenc
sequenc
light
report
data
set
present
silico
studi
support
sequenc
variat
determin
drug
interact
enhanc
benefit
multipl
daa
combin
comput
studi
show
impuls
start
broader
screen
small
natur
molecul
hcv
inhibitor
key
molecul
screen
analyz
studi
promis
starter
larg
scale
screen
list
larg
number
chemic
compound
avail
ligand
info
meta
databas
use
latest
virtual
screen
method
current
advanc
understand
molecular
basi
function
might
also
shoot
interest
design
develop
compound
target
key
residu
continu
research
recent
advanc
field
scienc
hope
pay
result
discoveri
natur
compound
use
laboratori
clinic
trial
lesser
side
effect
deeper
biochem
knowledg
complex
natur
due
cours
help
describ
molecular
mechan
ion
channel
fold
vital
achiev
effici
drug
human
anim
viru
particl
summari
align
entir
structur
genotyp
avail
model
protein
asia
middl
east
compar
dock
interact
known
inhibitor
well
natur
compound
known
antivir
properti
studi
build
way
research
depth
molecular
mechan
interact
hcv
genotyp
support
screen
specif
natur
inhibitor
avail
chemic
biolog
medicin
plant
extract
support
inform
dataset
genotyp
sequenc
multipl
align
